hVIVO plc
("hVIVO", the "Company" or
the "Group")
Notice of
results
hVIVO plc (AIM & Euronext: HVO),
a fast-growing specialist contract research organisation (CRO) and
world leader in testing infectious and respiratory disease products
using human challenge clinical trials, announces that it will
release its interim results for the six months ended 30 June 2024
on Tuesday 10 September 2024.
Analyst briefing
A briefing open to equity research
analysts will take place on Tuesday 10 September 2024 at 9.30am
BST. To register and for more details please contact Walbrook PR
on hvivo@walbrookpr.com.
Investor presentation
Yamin 'Mo' Khan, Chief Executive
Officer, and Stephen Pinkerton, Chief Financial Officer, will
provide a live presentation relating to the interim results via the
Investor Meet Company platform on Tuesday 10 September 2024 at
6.00pm BST.
The presentation is open to all
existing and potential shareholders. Questions can be submitted
pre-event via your Investor Meet Company dashboard up until 9am the
day before the meeting or at any time during the live
presentation.
Investors can sign up to Investor
Meet Company for free and add to meet hVIVO
here. Investors who already follow
hVIVO on the Investor Meet Company platform will automatically be
invited.
For
further information please contact:
|
hVIVO plc
|
+44 (0) 20
7756 1300
|
|
Yamin 'Mo' Khan, Chief Executive Officer
Stephen Pinkerton, Chief Financial
Officer
|
|
|
|
|
|
Cavendish Capital Markets Limited (Nominated Adviser and Joint
Broker)
|
+44 (0) 20
7220 0500
|
|
Geoff Nash, Camilla Hume, Nigel
Birks, Harriet Ward
|
|
|
|
|
|
Peel Hunt LLP (Joint Broker)
|
+44 (0)20
7418 8900
|
|
James Steel, Dr Christopher Golden
|
|
|
|
|
|
Davy (Euronext Growth Adviser and Joint
Broker)
|
+353 (0) 1
679 6363
|
|
Anthony Farrell, Niall
Gilchrist
|
|
|
|
|
|
Walbrook PR (Financial PR & IR)
Stephanie Cuthbert / Phillip
Marriage /
Louis Ashe-Jepson
|
+44 (0) 20
7933 8780 or hvivo@walbrookpr.com
+44 (0)
7796 794 663 / +44 (0) 7867 984 082 /
+44 (0) 7747 515 393
|
|
|
|
|
| |
Notes to
Editors
About
hVIVO
hVIVO plc
(ticker: HVO) is a fast-growing specialist contract research
organisation (CRO) and the world leader in testing infectious and
respiratory disease vaccines and therapeutics using human challenge
clinical trials. The Group provides end-to-end early clinical
development services to its large, established and growing repeat
client base, which includes four of the top 10 largest global
biopharma companies.
The Group's fast-growing services business
includes a unique portfolio of 11 human challenge models, with a
number of new models under development, to test a broad range of
infectious and respiratory disease products. The Group has world
class challenge agent manufacturing capabilities, specialist drug
development and clinical consultancy services via its Venn Life
Sciences brand, and a lab offering via its hLAB brand, which
includes virology, immunology biomarker and molecular testing. The
Group also offers additional clinical field trial services such as
patient recruitment and clinical trial site services.
hVIVO runs challenge trials in London -
its new state-of-the-art facilities in Canary Wharf opened in 2024
and is the world's largest commercial human challenge trial unit,
with highly specialised on-site virology and immunology
laboratories, and an outpatient unit. To recruit volunteers /
patients for its studies, the Group leverages its unique clinical
trial recruitment capability via its FluCamp volunteer screening
facilities in London and Manchester.